Dorlin Pharmaceuticals, Inc.

Baltimore, MD 21227

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $472K
First Award Date 09/30/96
Most Recent Award Date 09/30/01

Key Personnel

Last Name Name Awards Contact
Broedel Sheldon Edward Broedel 6
Raulli Robert Raulli 2

8 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 09/29/02

DESCRIPTION (provided by applicant): This proposal is to develop a method to prolong the shelf-life and increase the safety of human platelets with a unique method of sterilization. The method delivers an agent known to kill a range of microbial pathogens in vitro including many bacterial species known to contami...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/99 - 03/31/00

DESCRIPTION: The occurrence of fungal infections has escalated significantly in recent years and is expected to continue to increase for the foreseeable future. Unfortunately, only a limited number of antifungal drugs are currently available for use, due in part to a dearth of suitable targets. In this context...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/99 - 05/31/00

The occurrence of fungal infections has escalated significantly in recent years and is expected to continue to increase for the foreseeable future. Unfortunately, only a limited number of antifungal drugs are currently available for use, due in part to a dearth of suitable targets. In this context, the ultimate aim of the proposed investigation ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/15/99 - 08/31/00

This proposal is to develop a method to prolong the self-life and increase the safety of human platelets with a unique method of sterilization. The method delivers an agent known to kill a broad range of microbial pathogens in vitro including bacterial species known to contaminate platelet concentrates, as well as fungi, parasites, and viruses. ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/99 - 05/31/00

Systemic fungal infections have become a major concern in the health care industry. Inadequacies of available antifungal drugs have lead some professionals to conclude that current chemotherapeutic options are insufficient to meet this growing menace. To confront this challenge, new, safe and effective...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/98 - 03/15/99

The occurrence of fungal infections has escalated significantly in recent years and is expected to continue to increase for the foreseeable future. Unfortunately, only a limited number of antifungal drugs are currently available for use. This is due in part to the lack of defined targets available for e...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/98 - 05/31/99

Systemic fungal infections have become a major concern in the health care industry. Inadequacies of available antifungal drugs have lead some professionals to conclude that current chemotherapeutic options are insufficient to meet this growing menace. To confront this challenge, new, safe and effective...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/96 - 03/31/97